Promising immunotherapy against fungal diseases

References

• Patterson TF, Thompson GR 3rd, Denning DW, et al. Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63:433–442.
   PubMed Web of Science ®Google Scholar
• Lass-Florl C, Roilides E, Loffler J, et al. Minireview: host defence in invasive aspergillosis. Mycoses. 2013;56:403–413.
   PubMed Web of Science ®Google Scholar
• Medici NP, Del Poeta M. New insights on the development of fungal vaccines: from immunity to recent challenges. Mem Inst Oswaldo Cruz. 2015;110:966–973.
   PubMed Web of Science ®Google Scholar
• Romani L. Immunity to fungal infections. Nat Reviews Immunol. 2004;4:1–23.
   PubMed Web of Science ®Google Scholar
• Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2012;30:1–22.
   PubMed Web of Science ®Google Scholar
• Ogbomo H, Mody CH. Granule-dependent natural killer cell cytotoxicity to fungal pathogens. Front Immunol. 2016;7:692.
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr., Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197–216.
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801.
   PubMed Web of Science ®Google Scholar
• Romani L. Immunity to fungal infections. Nat Reviews Immunol. 2011;11:275–288.
   PubMed Web of Science ®Google Scholar
• Ruping MJ, Vehreschild JJ, Cornely OA. Patients at high risk of invasive fungal infections: when and how to treat. Drugs. 2008;68:1941–1962.
   PubMed Web of Science ®Google Scholar
• Puccetti P, Romani L, Bistoni F. A TH1-TH2-like switch in candidiasis: new perspectives for therapy. Trends Microbiol. 1995;3:237–240.
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. Adjunctive immune therapy for fungal infections. Clin Infect Dis. 2001;33:1048–1056.
   PubMed Web of Science ®Google Scholar
• Kapp A, Zeck-Kapp G. Activation of the oxidative metabolism in human polymorphonuclear neutrophilic granulocytes: the role of immuno-modulating cytokines. J Invest Dermatol. 1990;95:94S–9S.
   PubMed Web of Science ®Google Scholar
• Al-Shami A, Mahanna W, Naccache PH. Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils. Selective activation of Jak2, Stat3, and Stat5b. J Biol Chem. 1998;273:1058–1063.
   PubMed Web of Science ®Google Scholar
• Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood. 1993;81:1883–1888.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158–3167.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010;28:2914–2924.
   PubMed Web of Science ®Google Scholar
• Diamond RD, Clark RA. Damage to Aspergillus fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative microbicidal products of human neutrophils in vitro. Infect Immun. 1982;38:487–495.
   PubMed Web of Science ®Google Scholar
• Ellett F, Jorgensen J, Frydman GH, et al. Neutrophil interactions stimulate evasive hyphal branching by Aspergillus fumigatus. Plos Pathog. 2017;13:e1006154.
   PubMed Web of Science ®Google Scholar
• Gaviria JM, Van Burik JA, Dale DC, et al. Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. J Infect Dis. 1999;179:1038–1041.
   PubMed Web of Science ®Google Scholar
• Gil-Lamaignere C, Winn RM, Simitsopoulou M, et al. Inteferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp: comparison with Aspergillus spp. Med Mycol. 2005;43:253–260.
   PubMed Web of Science ®Google Scholar
• Safdar A, Rodriguez G, Ohmagari N, et al. The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer. 2005;103:731–739.
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. Aids. 2012;26:1105–1113.
   PubMed Web of Science ®Google Scholar
• Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50:291–322.
   PubMed Web of Science ®Google Scholar
• Roilides E, Lamaignere CG, Farmaki E. Cytokines in immunodeficient patients with invasive fungal infections: an emerging therapy. Int J Infect Dis. 2002;6:154–163.
   PubMedGoogle Scholar
• Ferrante A. Tumor necrosis factor alpha potentiates neutrophil antimicrobial activity: increased fungicidal activity against Torulopsis glabrata and Candida albicans and associated increases in oxygen radical production and lysosomal enzyme release. Infect Immun. 1989;57:2115–2122.
   PubMed Web of Science ®Google Scholar
• Djeu JY, Blanchard DK, Halkias D, et al. Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-gamma and tumor necrosis factor. J Immunology. 1986;137:2980–2984.
   PubMed Web of Science ®Google Scholar
• Nagai H, Guo J, Choi H, et al. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis. 1995;172:1554–1560.
   PubMed Web of Science ®Google Scholar
• Mehrad B, Strieter RM, Standiford TJ. Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. J Immunology. 1999;162:1633–1640.
   PubMed Web of Science ®Google Scholar
• Winn RM, Gil-Lamaignere C, Roilides E, et al. Selective effects of interleukin (IL)-15 on antifungal activity and IL-8 release by polymorphonuclear leukocytes in response to hyphae of Aspergillus species. J Infect Dis. 2003;188:585–590.
   PubMed Web of Science ®Google Scholar
• Hubel K, Carter RA, Liles WC, et al. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion. 2002;42:1414–1421.
   PubMed Web of Science ®Google Scholar
• Price TH, Bowden RA, Boeckh M, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood. 2000;95:3302–3309.
   PubMed Web of Science ®Google Scholar
• Price TH, Boeckh M, Harrison RW, et al. Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. Blood. 2015;126:2153–2161.
   PubMed Web of Science ®Google Scholar
• Seidel MG, Peters C, Wacker A, et al. Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant. 2008;42:679–684.
   PubMed Web of Science ®Google Scholar
• BitMansour A, Burns SM, Traver D, et al. Myeloid progenitors protect against invasive aspergillosis and Pseudomonas aeruginosa infection following hematopoietic stem cell transplantation. Blood. 2002;100:4660–4667.
   PubMed Web of Science ®Google Scholar
• BitMansour A, Cao TM, Chao S, et al. Single infusion of myeloid progenitors reduces death from Aspergillus fumigatus following chemotherapy-induced neutropenia. Blood. 2005;105:3535–3537.
   PubMed Web of Science ®Google Scholar
• Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9:593–608.
   PubMed Web of Science ®Google Scholar
• Di Francesco P, Gaziano R, Casalinuovo IA, et al. Combined effect of fluconazole and thymosin alpha 1 on systemic candidiasis in mice immunosuppressed by morphine treatments. Clin Exp Immunol. 1994;97:347–352.
   PubMed Web of Science ®Google Scholar
• Braem SG, Rooijakkers SH, Van Kessel KP, et al. Effective neutrophil phagocytosis of Aspergillus fumigatus Is mediated by classical pathway complement activation. J Innate Immun. 2015;7:364–374.
   PubMed Web of Science ®Google Scholar
• Mambula SS, Sau K, Henneke P, et al. Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J Biol Chem. 2002;277:39320–39326.
   PubMed Web of Science ®Google Scholar
• Wozniok I, Hornbach A, Schmitt C, et al. Induction of ERK-kinase signalling triggers morphotype-specific killing of Candida albicans filaments by human neutrophils. Cell Microbiol. 2008;10:807–820.
   PubMed Web of Science ®Google Scholar
• Bellocchio S, Montagnoli C, Bozza S, et al. The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunology. 2004;172:3059–3069.
   PubMed Web of Science ®Google Scholar
• Bellocchio S, Gaziano R, Bozza S, et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J Antimicrob Chemother. 2005;55:214–222.
   PubMed Web of Science ®Google Scholar
• Carvalho A, Cunha C, Bistoni F, et al. Immunotherapy of aspergillosis. Clin Microbiol Infect. 2012;18:120–125.
   PubMed Web of Science ®Google Scholar
• Garlanda C, Hirsch E, Bozza S, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature. 2002;420:182–186.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Cassatella MA, Costantini C, et al. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Reviews Immunol. 2011;11:519–531.
   PubMed Web of Science ®Google Scholar
• Cunha C, Aversa F, Lacerda JF, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med. 2014;370:421–432.
   PubMed Web of Science ®Google Scholar
• D’Angelo C, De Luca A, Zelante T, et al. Exogenous pentraxin 3 restores antifungal resistance and restrains inflammation in murine chronic granulomatous disease. J Immunology. 2009;183:4609–4618.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J. Macrophage function activating cytokines: potential clinical application. Crit Rev Oncol Hematol. 1993;14:153–171.
   PubMed Web of Science ®Google Scholar
• Cenci E, Bartocci A, Puccetti P, et al. Macrophage colony-stimulating factor in murine candidiasis: serum and tissue levels during infection and protective effect of exogenous administration. Infect Immun. 1991;59:868–872.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J. Use of macrophage colony-stimulating factor in the treatment of fungal infections. Clin Infect Dis. 1998;26:1279–1281.
   PubMed Web of Science ®Google Scholar
• Aukerman SL, Middleton S, Sampson-Johannes A, et al. Biological preclinical activity of macrophage colony-stimulating factor, M-CSF. In: Symann M, Morstyn PQ,G, editor. Growth Factors and Interleukins: biology and Clinical Applications 1992. Macclesfield: Caldwell Communications; 1992. p. 79–93.
   Google Scholar
• Nemunaitis J, Shannon-Dorcy K, Appelbaum FR, et al. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood. 1993;82:1422–1427.
   PubMed Web of Science ®Google Scholar
• Safdar A, Rodriguez G, Zuniga J, et al. Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease. Acta Haematol. 2013;129:26–34.
   PubMed Web of Science ®Google Scholar
• Roilides E, Blake C, Holmes A, et al. Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol. 1996;34:63–69.
   PubMedGoogle Scholar
• Netea MG, Kullberg BJ, Jacobs LE, et al. Van der Meer JW. Chlamydia pneumoniae stimulates IFN-gamma synthesis through MyD88-dependent, TLR2- and TLR4-independent induction of IL-18 release. J Immunology. 2004;173:1477–1482.
   PubMed Web of Science ®Google Scholar
• Romani L, Puccetti P. Controlling pathogenic inflammation to fungi. Expert Rev Anti Infect Ther. 2007;5:1007–1017.
   PubMed Web of Science ®Google Scholar
• Romani L, Puccetti P. Protective tolerance to fungi: the role of IL-10 and tryptophan catabolism. Trends Microbiol. 2006;14:183–189.
   PubMed Web of Science ®Google Scholar
• Steger MB,M, Latgé JP, Wagener J, et al. An efficient first line of immune defense is initiated by Aspergillus fumigatus devoid of cell wall β-1,3-glucan.  Under review.
   Google Scholar
• Posch W, Steger M, Knackmuss U, et al. Complement-Opsonized HIV-1 Overcomes Restriction in Dendritic Cells. Plos Pathog. 2015;11:e1005005.
   PubMed Web of Science ®Google Scholar
• Wilflingseder D, Schroll A, Hackl H, et al. Immediate T-Helper17 Polarization Upon Triggering CD11b/c on HIV-Exposed Dendritic Cells. J Infect Dis. 2015;212:44–56.
   PubMed Web of Science ®Google Scholar
• Shao C, Qu J, He L, et al. Dendritic cells transduced with an adenovirus vector encoding interleukin-12 are a potent vaccine for invasive pulmonary aspergillosis. Genes Immun. 2005;6:103–114.
   PubMed Web of Science ®Google Scholar
• Bozza S, Perruccio K, Montagnoli C, et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood. 2003;102:3807–3814.
   PubMed Web of Science ®Google Scholar
• Roy RM, Klein BS. Dendritic cells in antifungal immunity and vaccine design. Cell Host Microbe. 2012;11:436–446.
   PubMed Web of Science ®Google Scholar
• Abdel-Motal UM, Dahmen J, Liu T, et al. External glycopeptide binding to MHC class-I in relation to expression of TAP transporters, beta 2-microglobulin and to pH. Immunol Lett. 1996;54:31–35.
   PubMed Web of Science ®Google Scholar
• Li SS, Kyei SK, Timm-McCann M, et al. The NK receptor NKp30 mediates direct fungal recognition and killing and is diminished in NK cells from HIV-infected patients. Cell Host Microbe. 2013;14:387–397.
   PubMed Web of Science ®Google Scholar
• Stuehler C, Khanna N, Bozza S, et al. Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood. 2011;117:5881–5891.
   PubMed Web of Science ®Google Scholar
• Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106:4397–4406.
   PubMed Web of Science ®Google Scholar
• Schmidt S, Tramsen L, Perkhofer S, et al. Characterization of the cellular immune responses to Rhizopus oryzae with potential impact on immunotherapeutic strategies in hematopoietic stem cell transplantation. J Infect Dis. 2012;206:135–139.
   PubMed Web of Science ®Google Scholar
• Hebart H, Bollinger C, Fisch P, et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood. 2002;100:4521–4528.
   PubMed Web of Science ®Google Scholar
• Di Ianni M, Falzetti F, Carotti A, et al. Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. Best Pract Res Clin Haematol. 2011;24:459–466.
   PubMed Web of Science ®Google Scholar
• Nanjappa SG, Heninger E, Wuthrich M, et al. Protective antifungal memory CD8(+) T cells are maintained in the absence of CD4(+) T cell help and cognate antigen in mice. J Clin Invest. 2012;122:987–999.
   PubMed Web of Science ®Google Scholar
• Ma LL, Spurrell JC, Wang JF, et al. CD8 T cell-mediated killing of Cryptococcus neoformans requires granulysin and is dependent on CD4 T cells and IL-15. J Immunology. 2002;169:5787–5795.
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Kimmel B, Herrmann T, et al. Inhibition of phosphoantigen-mediated gammadelta T-cell proliferation by CD4+ CD25+ FoxP3+ regulatory T cells. Immunology. 2009;126:256–267.
   PubMed Web of Science ®Google Scholar
• Delsing CE, Gresnigt MS, Leentjens J, et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect Dis. 2014;14:166.
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Van De Veerdonk F, Netea MG. Immunotherapy: a potential adjunctive treatment for fungal infection. Curr Opin Infect Dis. 2014;27:511–516.
   PubMed Web of Science ®Google Scholar
• Segal BH, Kwon-Chung J, Walsh TJ, et al. Immunotherapy for fungal infections. Clin Infect Dis. 2006;42:507–515.
   PubMed Web of Science ®Google Scholar
• Clemons KV, Martinez M, Chen V, et al. Protection against experimental aspergillosis by heat-killed yeast is not antibody dependent. Med Mycol. 2014;52:422–426.
   PubMed Web of Science ®Google Scholar
• Diaz-Arevalo D, Bagramyan K, Hong TB, et al. CD4+ T cells mediate the protective effect of the recombinant Asp f3-based anti-aspergillosis vaccine. Infect Immun. 2011;79:2257–2266.
   PubMed Web of Science ®Google Scholar
• Marr KA, Datta K, Pirofski LA, et al. Cryptococcus gattii infection in healthy hosts: a sentinel for subclinical immunodeficiency? Clin Infect Dis. 2012;54:153–154.
   PubMed Web of Science ®Google Scholar
• Malphettes M, Gerard L, Galicier L, et al. Good syndrome: an adult-onset immunodeficiency remarkable for its high incidence of invasive infections and autoimmune complications. Clin Infect Dis. 2015;61:e13–9.
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe. 2012;11:447–456.
   PubMed Web of Science ®Google Scholar
• Rivera J, Casadevall A. Mouse genetic background is a major determinant of isotype-related differences for antibody-mediated protective efficacy against Cryptococcus neoformans. J Immunology. 2005;174:8017–8026.
   PubMed Web of Science ®Google Scholar
• Maitta RW, Datta K, Pirofski LA. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan. Vaccine. 2004;22:4062–4068.
   PubMed Web of Science ®Google Scholar
• Torosantucci A, Chiani P, Bromuro C, et al. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. Plos One. 2009;4:e5392.
   PubMed Web of Science ®Google Scholar
• Rachini A, Pietrella D, Lupo P, et al. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun. 2007;75:5085–5094.
   PubMed Web of Science ®Google Scholar
• Pachl J, Svoboda P, Jacobs F, et al. Mycograb Invasive Candidiasis Study G. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis. 2006;42:1404–1413.
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. A new synthesis for antibody-mediated immunity. Nat Immunol. 2011;13:21–28.
   PubMed Web of Science ®Google Scholar
• Iannitti RG, Carvalho A, Romani L. From memory to antifungal vaccine design. Trends Immunol. 2012;33:467–474.
   PubMed Web of Science ®Google Scholar
• Nanjappa SG, Klein BS. Vaccine immunity against fungal infections. Curr Opin Immunol. 2014;28:27–33.
   PubMed Web of Science ®Google Scholar
• Edwards JE Jr. Fungal cell wall vaccines: an update. J Med Microbiol. 2012;61:895–903.
   PubMed Web of Science ®Google Scholar
• Bozza S, Clavaud C, Giovannini G, et al. Immune sensing of Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the impact on Th immunity and vaccination. J Immunology. 2009;183:2407–2414.
   PubMed Web of Science ®Google Scholar
• Ito JI, Lyons JM, Hong TB, et al. Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis. Infect Immun. 2006;74:5075–5084.
   PubMed Web of Science ®Google Scholar
• Schmidt CS, White CJ, Ibrahim AS, et al. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine. 2012;30:7594–7600.
   PubMed Web of Science ®Google Scholar
• Liu M, Clemons KV, Bigos M, et al. Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection. Vaccine. 2011;29:1745–1753.
   PubMed Web of Science ®Google Scholar
• Levitz SM. Aspergillus vaccines: hardly worth studying or worthy of hard study? Med Mycol. 2017;55:103–108.
   PubMed Web of Science ®Google Scholar
• Cassone A. Fungal vaccines: real progress from real challenges. Lancet Infect Dis. 2008;8:114–124.
   PubMed Web of Science ®Google Scholar
• Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640–3645.
   PubMed Web of Science ®Google Scholar
• Aigner M, Lass-Florl C. Treatment of drug-resistant Aspergillus infection. Expert Opin Pharmacother. 2015;16:2267–2270.
   PubMed Web of Science ®Google Scholar
• Springer J, Lackner M, Nachbaur D, et al. Prospective multicentre PCR-based Aspergillus DNA screening in high-risk patients with and without primary antifungal mould prophylaxis. Clin Microbiol Infect. 2016;22:80–86.
   PubMed Web of Science ®Google Scholar